Back to trial
Eligibility Pre-Screening
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.
Question 1 of 60%